ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > not happening today

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Jan 20, 2023 3:49pm

174 Views

Post# 35236393

RE:not happening today

I am really looking to see if what we know is obvious again " with plaque reduction there is the side effect of areia and in this case they are saying " the speed of plaque removal stopped ,treatments " wondering if it's actually the prevalence of brain bleeding that may have stopped treatments ...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China